Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1967 1
1970 1
1971 2
1973 1
1975 1
1977 1
1979 1
1980 2
1985 1
1986 1
1987 4
1988 2
1989 1
1992 1
1995 2
1997 2
1998 2
1999 3
2000 1
2001 3
2002 4
2003 6
2004 9
2005 3
2006 2
2007 1
2008 3
2009 9
2010 4
2011 5
2012 4
2013 10
2014 11
2015 7
2016 9
2017 5
2018 3
2019 7
2020 9
2021 15
2022 18
2023 10
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Results by year

Filters applied: . Clear all
Page 1
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Sato A, et al. Among authors: imai c. Lancet Haematol. 2023 Jun;10(6):e419-e432. doi: 10.1016/S2352-3026(23)00072-8. Epub 2023 May 8. Lancet Haematol. 2023. PMID: 37167992 Clinical Trial.
Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, De Moerloose B, Schmiegelow K, Burns MA, Elitzur S, Pieters R, Attarbaschi A, Yeoh A, Pui CH, Stary J, Cario G, Bodmer N, Moorman AV, Buldini B, Vora A, Valsecchi MG. Raetz EA, et al. Among authors: imai c. J Clin Oncol. 2023 Nov 10;41(32):5025-5034. doi: 10.1200/JCO.23.00088. Epub 2023 Jul 24. J Clin Oncol. 2023. PMID: 37487146
4-1BB chimeric antigen receptors.
Campana D, Schwarz H, Imai C. Campana D, et al. Among authors: imai c. Cancer J. 2014 Mar-Apr;20(2):134-40. doi: 10.1097/PPO.0000000000000028. Cancer J. 2014. PMID: 24667959 Review.
Epigenetic upregulation of Schlafen11 renders 
WNT- and SHH-activated medulloblastomas sensitive to cisplatin.
Nakata S, Murai J, Okada M, Takahashi H, Findlay TH, Malebranche K, Parthasarathy A, Miyashita S, Gabdulkhaev R, Benkimoun I, Druillennec S, Chabi S, Hawkins E, Miyahara H, Tateishi K, Yamashita S, Yamada S, Saito T, On J, Watanabe J, Tsukamoto Y, Yoshimura J, Oishi M, Nakano T, Imamura M, Imai C, Yamamoto T, Takeshima H, Sasaki AT, Rodriguez FJ, Nobusawa S, Varlet P, Pouponnot C, Osuka S, Pommier Y, Kakita A, Fujii Y, Raabe EH, Eberhart CG, Natsumeda M. Nakata S, et al. Among authors: imai c. Neuro Oncol. 2023 May 4;25(5):899-912. doi: 10.1093/neuonc/noac243. Neuro Oncol. 2023. PMID: 36273330 Free PMC article.
Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia.
Imai C, Sato A, Hiwatari M, Shimomura Y, Hori T, Suenobu S, Imamura T, Hara J, Hasegawa D, Takahashi H, Moriya K, Katayama S, Tomizawa D, Moritake H, Taga T, Horibe K, Koh K, Manabe A, Okamoto Y. Imai C, et al. Int J Hematol. 2023 Jul;118(1):99-106. doi: 10.1007/s12185-023-03600-3. Epub 2023 Apr 10. Int J Hematol. 2023. PMID: 37037958
Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients.
Geier CB, Ellison M, Cruz R, Pawar S, Leiss-Piller A, Zmajkovicova K, McNulty SM, Yilmaz M, Evans MO 2nd, Gordon S, Ujhazi B, Wiest I, Abolhassani H, Aghamohammadi A, Barmettler S, Bhar S, Bondarenko A, Bolyard AA, Buchbinder D, Cada M, Cavieres M, Connelly JA, Dale DC, Deordieva E, Dorsey MJ, Drysdale SB, Ehl S, Elfeky R, Fioredda F, Firkin F, Förster-Waldl E, Geng B, Goda V, Gonzalez-Granado L, Grunebaum E, Grzesk E, Henrickson SE, Hilfanova A, Hiwatari M, Imai C, Ip W, Jyonouchi S, Kanegane H, Kawahara Y, Khojah AM, Kim VH, Kojić M, Kołtan S, Krivan G, Langguth D, Lau YL, Leung D, Miano M, Mersyanova I, Mousallem T, Muskat M, Naoum FA, Noronha SA, Ouederni M, Ozono S, Richmond GW, Sakovich I, Salzer U, Schuetz C, Seeborg FO, Sharapova SO, Sockel K, Volokha A, von Bonin M, Warnatz K, Wegehaupt O, Weinberg GA, Wong KJ, Worth A, Yu H, Zharankova Y, Zhao X, Devlin L, Badarau A, Csomos K, Keszei M, Pereira J, Taveras AG, Beaussant-Cohen SL, Ong MS, Shcherbina A, Walter JE. Geier CB, et al. Among authors: imai c. J Clin Immunol. 2022 Nov;42(8):1748-1765. doi: 10.1007/s10875-022-01312-7. Epub 2022 Aug 10. J Clin Immunol. 2022. PMID: 35947323 Free PMC article.
Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
Sato T, Yoshida K, Toki T, Kanezaki R, Terui K, Saiki R, Ojima M, Ochi Y, Mizuno S, Yoshihara M, Uechi T, Kenmochi N, Tanaka S, Matsubayashi J, Kisai K, Kudo K, Yuzawa K, Takahashi Y, Tanaka T, Yamamoto Y, Kobayashi A, Kamio T, Sasaki S, Shiraishi Y, Chiba K, Tanaka H, Muramatsu H, Hama A, Hasegawa D, Sato A, Koh K, Karakawa S, Kobayashi M, Hara J, Taneyama Y, Imai C, Hasegawa D, Fujita N, Yoshitomi M, Iwamoto S, Yamato G, Saida S, Kiyokawa N, Deguchi T, Ito M, Matsuo H, Adachi S Prof, Hayashi Y, Taga T, Moriya Saito A, Horibe K, Watanabe K, Tomizawa D, Miyano S, Takahashi S, Ogawa S, Ito E. Sato T, et al. Among authors: imai c. Blood. 2024 Mar 21:blood.2023022247. doi: 10.1182/blood.2023022247. Online ahead of print. Blood. 2024. PMID: 38513239
Drug-induced panniculitis in a child with acute lymphoblastic leukemia.
Iwabuchi H, Takachi T, Kubo N, Imamura M, Umezu H, Saitoh A, Imai C. Iwabuchi H, et al. Among authors: imai c. Pediatr Blood Cancer. 2022 May;69(5):e29501. doi: 10.1002/pbc.29501. Epub 2021 Dec 10. Pediatr Blood Cancer. 2022. PMID: 34889502 No abstract available.
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S, Ando M, Ando J, Ishii M, Yamaguchi T, Yamazaki S, Toyota T, Ohara K, Ohtaka M, Nakanishi M, Shin C, Ota Y, Nakashima K, Ohshima K, Imai C, Nakazawa Y, Nakauchi H, Komatsu N. Harada S, et al. Among authors: imai c. Mol Ther. 2022 Feb 2;30(2):534-549. doi: 10.1016/j.ymthe.2021.10.006. Epub 2021 Oct 8. Mol Ther. 2022. PMID: 34628050 Free PMC article.
184 results